EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Magnetic Resonance‐Guided Laser Interstitial Thermal Therapy Using Dual‐Wavelength Dual‐Output Laser Within Two Probe Trajectories for Treatment of Drug‐Resistant Epilepsy

Jingquan Lin, Wei Gao, Yuqi Ying, Ahmed Abdulsalam Ali Bakrbaldawi, Zhoule Zhu, Chengwei Cai, Xinxia Guo, Jianmin Zhang iD, Junming Zhu iD

CNS Neuroscience & Therapeutics · 2024

DOI: 10.1111/cns.70118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Jingquan Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Laser Therapy, Magnetic Resonance Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Pioneer" and "Leading Goose" R&D Program of Zhejiang, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Magnetic resonance‐guided laser interstitial thermal therapy (MRgLITT) is a novel tool and a minimally invasive treatment to drug‐resistant epilepsy (DRE). The focus of this research was to evaluate the effectiveness and safety of the newly developed dual‐wavelength dual‐output MRgLITT system LaserRO within two probe trajectories in treating DRE patients.

Methods

This is a retrospective analysis conducted at a single center, examining patients with DRE who received treatment with the LaserRO MRgLITT system. The system utilizes a sophisticated laser technology that can be configured as conventional single output for single wavelength or innovative dual outputs for dual wavelengths. The study involved a comprehensive review of patient information, encompassing demographics, seizure history, details related to the surgical parameters, and the subsequent clinical results. Primary outcome was post‐operation seizure outcome defined as Engel Scale Class at the end of follow‐up time.

Results

This study included a total of eight DRE patients received MRgLITT surgery between August 2022 and October 2023. Out of these, there were four mesial temporal lobe epilepsy (MTLE), three focal cortical dysplasia (FCD), and one cavernous malformation (CM) patients. Within the two probe trajectories, seven patients had single wavelength (980 or 1064 nm) laser treatment and one patient had dual‐wavelength (980 and 1064 nm) laser treatment. The median age of the patients was 27 (22–31) years, with a median follow‐up period of 9.7 (8.4–12.1) months. The mean BMI was recorded at 20.24 ± 2.95 kg/m 2 , and epilepsy history was 13 ± 6 years. The median intraoperative blood loss was 5 (5–9) mL, operation time was 231 (169–254) minutes, and length of stay (LOS) was 3 (3–5) days. The mean ablation volume ratio was 96.52% ± 3.67%. In terms of outcomes, over a median follow‐up time of 9.7 (range 8.4–12.1) months, there were two patients got Engel I, five patients got seizure‐free, and one patient decreased 75% seizure. Importantly, no serious complications following the procedures occurred.

Conclusions

The preliminary results indicate that the MRgLITT procedure, which operates dual‐output laser with single or dual wavelengths (980/1064 nm) within the two trajectories, is both effective and safe as a minimally invasive approach for different types of DRE patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistant EpilepsyLaser TherapyMagnetic Resonance ImagingHumansFemaleMaleAdultRetrospective StudiesYoung AdultTreatment OutcomeMiddle AgedAdolescentSurgery, Computer-Assisted

Stichwörter der Autor:innen

Epilepsyintraoperative MRIlaser ablationlaser interstitial thermal therapyseizure

Autor:innen und Institutionen

  • Department of Neurosurgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Epilepsy Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Brain Research Institute, Zhejiang University, Hangzhou, China.
  • Key Laboratory of Precise Treatment and Clinical Translational Research of Neurological Diseases of Zhejiang Province, Hangzhou, China.
  • Clinical Research Center for Neurological Diseases of Zhejiang Province, Hangzhou, China.
  • State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China.

ORCID-Profile: Jianmin Zhang, Junming Zhu

Förderung

  • "Pioneer" and "Leading Goose" R&D Program of Zhejiang
  • National Natural Science Foundation of China

Zitieren

APA

Lin, J., Gao, W., Ying, Y., Bakrbaldawi, A. A. A., Zhu, Z., Cai, C., Guo, X., Zhang, J., & Zhu, J. (2024). Magnetic Resonance‐Guided Laser Interstitial Thermal Therapy Using Dual‐Wavelength Dual‐Output Laser Within Two Probe Trajectories for Treatment of Drug‐Resistant Epilepsy. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70118

Vancouver

Lin J, Gao W, Ying Y, Bakrbaldawi AAA, Zhu Z, Cai C, et al. Magnetic Resonance‐Guided Laser Interstitial Thermal Therapy Using Dual‐Wavelength Dual‐Output Laser Within Two Probe Trajectories for Treatment of Drug‐Resistant Epilepsy. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.70118

BibTeX
@article{Lin2024,
  author = {Lin, Jingquan and Gao, Wei and Ying, Yuqi and Bakrbaldawi, Ahmed Abdulsalam Ali and Zhu, Zhoule and Cai, Chengwei and Guo, Xinxia and Zhang, Jianmin and Zhu, Junming},
  title = {Magnetic Resonance‐Guided Laser Interstitial Thermal Therapy Using Dual‐Wavelength Dual‐Output Laser Within Two Probe Trajectories for Treatment of Drug‐Resistant Epilepsy},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  doi = {10.1111/cns.70118}
}
Kostenlos starten →